[go: up one dir, main page]

PE20151867A1 - Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados - Google Patents

Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados

Info

Publication number
PE20151867A1
PE20151867A1 PE2015002278A PE2015002278A PE20151867A1 PE 20151867 A1 PE20151867 A1 PE 20151867A1 PE 2015002278 A PE2015002278 A PE 2015002278A PE 2015002278 A PE2015002278 A PE 2015002278A PE 20151867 A1 PE20151867 A1 PE 20151867A1
Authority
PE
Peru
Prior art keywords
polypeptides
rsv
prefusion
soluble
respiratory syncitial
Prior art date
Application number
PE2015002278A
Other languages
English (en)
Inventor
Johannes Petrus Maria Langedijk
Anders Krarup
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151867(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of PE20151867A1 publication Critical patent/PE20151867A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A POLIPEPTIDOS F DE PREFUSION DEL VIRUS SINCICIAL RESPIRATORIO (RSV) ESTABLES, COMPOSICIONES INMUNOGENICAS QUE COMPRENDEN DICHOS POLIPEPTIDOS Y SUS USOS EN LA PREVENCION Y/O EL TRATAMIENTO DE UNA INFECCION POR RSV
PE2015002278A 2013-04-25 2014-04-24 Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados PE20151867A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13165402 2013-04-25

Publications (1)

Publication Number Publication Date
PE20151867A1 true PE20151867A1 (es) 2016-01-07

Family

ID=48326107

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002278A PE20151867A1 (es) 2013-04-25 2014-04-24 Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados

Country Status (33)

Country Link
US (3) US10899800B2 (es)
EP (2) EP3488864A1 (es)
JP (1) JP6469081B2 (es)
KR (1) KR102236497B1 (es)
CN (2) CN105188745B (es)
AP (1) AP2015008815A0 (es)
AR (1) AR096113A1 (es)
AU (1) AU2014259474B2 (es)
CA (1) CA2910067C (es)
CL (1) CL2015003124A1 (es)
CY (1) CY1121600T1 (es)
DK (1) DK2988780T3 (es)
EA (2) EA039803B1 (es)
ES (1) ES2715378T3 (es)
HR (1) HRP20190175T1 (es)
HU (1) HUE041659T2 (es)
IL (1) IL242186B (es)
LT (1) LT2988780T (es)
ME (1) ME03442B (es)
MX (1) MX361774B (es)
MY (2) MY181066A (es)
PE (1) PE20151867A1 (es)
PH (1) PH12015502377B1 (es)
PL (1) PL2988780T3 (es)
PT (1) PT2988780T (es)
RS (1) RS58436B1 (es)
SG (1) SG11201508567XA (es)
SI (1) SI2988780T1 (es)
SM (1) SMT201900138T1 (es)
TR (1) TR201902513T4 (es)
TW (1) TWI663175B (es)
WO (1) WO2014174018A1 (es)
ZA (1) ZA201507912B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP3488864A1 (en) * 2013-04-25 2019-05-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
US10744193B2 (en) 2015-03-30 2020-08-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic RSV polypeptides
CN116059336A (zh) 2015-07-07 2023-05-05 扬森疫苗与预防公司 针对rsv的疫苗
EP3319634B1 (en) * 2015-07-07 2019-08-21 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP4019044A3 (en) * 2015-09-02 2022-08-24 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
RU2730625C2 (ru) 2015-09-03 2020-08-24 Новавакс, Инк. Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
PE20181354A1 (es) 2015-12-23 2018-08-22 Pfizer Mutantes de proteina f de rsv
JP7065030B2 (ja) 2016-02-03 2022-05-11 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｒｓｖの処置のための組合せ製品
AU2017242020B2 (en) 2016-03-29 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
MD3439672T2 (ro) 2016-04-05 2021-04-30 Janssen Vaccines & Prevention Bv Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
DK3464331T3 (da) * 2016-05-30 2021-01-18 Janssen Vaccines & Prevention Bv Stabiliserede præfusions-rsv f-proteiner
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
LT3606942T (lt) 2017-04-04 2025-10-10 Savaiminės sąrankos baltymų nanostruktūros, eksponuojančios paramiksoviruso ir (arba) pneumoviruso f baltymus ir jų naudojimas
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
EP3658118B1 (en) 2017-07-24 2025-03-19 Novavax, Inc. Methods and compositions for treating respiratory disease
EA202090738A1 (ru) * 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
KR102700187B1 (ko) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
CN112469436B (zh) 2018-03-19 2025-03-14 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
US12370252B2 (en) * 2018-10-29 2025-07-29 Emory University RSV virus-like particles and methods of use thereof
PH12021550974A1 (en) 2018-11-13 2022-05-02 Janssen Vaccines & Prevention Bv Stablized pre-fusion rsv f proteins
CN109851678A (zh) * 2019-03-07 2019-06-07 苏州宇之波生物科技有限公司 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
BR112021022087A2 (pt) 2019-05-15 2021-12-28 Janssen Vaccines & Prevention Bv Coadministração de vacina sazonal contra influenza e vacina contra vírus respiratório sincicial à base de adenovírus
AU2020275910A1 (en) 2019-05-15 2021-11-04 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
JP2022546813A (ja) 2019-09-04 2022-11-09 ユニヴァーシティ オブ ワシントン パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
JP2023519740A (ja) 2020-04-02 2023-05-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 安定化型ワクチン組成物
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
CN112220921B (zh) 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN114195867B (zh) * 2021-12-15 2024-05-03 北京交通大学 一种rsv融合前f蛋白、表达质粒、细胞株和rsv疫苗组合物
EP4448802A1 (en) 2021-12-16 2024-10-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
KR20250071244A (ko) * 2022-09-29 2025-05-21 베이징 베네윌 테크놀로지 디벨롭먼트 컴퍼니 리미티드 융합 전 형태의 호흡기 세포융합 바이러스 재조합 융합 단백질, 이의 제조 방법 및 용도
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
JP2026500218A (ja) 2022-12-11 2026-01-06 ファイザー・インク インフルエンザおよびｒｓｖに対する免疫原性組成物
CN120659803A (zh) * 2023-01-17 2025-09-16 斯克里普斯研究学院 工程化副黏病毒可溶性融合（f）蛋白及相关疫苗
EP4651889A1 (en) 2023-01-18 2025-11-26 Pfizer Inc. Vaccines against respiratory diseases
WO2024167866A2 (en) * 2023-02-06 2024-08-15 Cyanvac Llc Modified piv5 vaccine vectors: methods of making and uses
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
WO2024251281A1 (zh) 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
WO2025012756A1 (en) 2023-07-07 2025-01-16 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
CN119462859A (zh) * 2023-08-09 2025-02-18 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、疫苗及其应用
CN116785421B (zh) * 2023-08-21 2024-01-09 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种牛呼吸道合胞体病毒的mRNA疫苗及其应用
WO2025051250A1 (zh) * 2023-09-07 2025-03-13 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用
WO2025059498A2 (en) * 2023-09-15 2025-03-20 Icosavax, Inc. Viral proteins and nanostructures and uses thereof
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
CN117736278B (zh) * 2023-12-25 2025-02-07 英诺特（唐山）生物技术有限公司 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
WO2025149032A1 (en) * 2024-01-11 2025-07-17 Immorna (hangzhou) Biotechnology Co., Ltd. Respiratory syncytial virus vaccine compositions and their use
CN117586357B (zh) * 2024-01-19 2024-07-09 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
CN121022942A (zh) * 2024-05-27 2025-11-28 广州国家实验室 腺相关病毒载体在制备防治rsv感染和/或rsv引起的疾病的药物中的应用
CN120192385B (zh) * 2025-02-07 2025-11-11 复星安特金(成都)生物制药有限公司 Rsv f蛋白突变体及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
SK181098A3 (en) 1996-07-01 1999-07-12 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
EP0968284B1 (en) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
HU226015B1 (en) 1998-02-17 2008-02-28 Schering Corp Compositions and preparations comprising viruses
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
DE69940354D1 (de) 1998-11-16 2009-03-12 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
EP1550722B1 (en) 1999-05-17 2007-06-13 Crucell Holland B.V. Recombinant human adenovirus serotype 35
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
JP5118798B2 (ja) 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
CA2415688A1 (en) 2000-05-08 2001-11-15 Anand Rao Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
CA2469721A1 (en) 2002-01-18 2003-07-31 Schering Aktiengesellschaft Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
EP1506287B1 (en) 2002-05-14 2007-04-25 Merck & Co., Inc. Methods of adenovirus purification
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003268210A1 (en) 2002-08-28 2004-03-19 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
LT2163260T (lt) 2004-01-23 2017-06-26 Msd Italia S.R.L. Šimpanzės adenoviruso vakcinos nešikliai
WO2005080556A2 (en) 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
AU2006233800B2 (en) 2005-04-11 2011-07-07 Crucell Holland B.V. Virus purification using ultrafiltration
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2007110409A1 (en) 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
US8772256B2 (en) 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
EP4670734A2 (en) * 2007-12-24 2025-12-31 GlaxoSmithKline Biologicals S.A. RECOMBINANT RSV ANTIGENS
WO2010014975A2 (en) 2008-08-01 2010-02-04 Academia Sinica Use of microrna signatures for assessing risk levels of neuroblastoma patients
NZ593235A (en) 2008-11-03 2013-02-22 Crucell Holland Bv Method for the production of recombinant adenovirus serotype 35
SG2014007959A (en) 2009-02-02 2014-03-28 Okair S Ag Simian adenovirus nucleic acid- and amino acid- sequences, vectors containing same, and uses thereof
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
EP2453918B1 (en) * 2009-07-15 2015-12-16 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
BR112012008507B8 (pt) 2009-10-15 2021-05-25 Crucell Holland Bv método para purificar partículas de adenovírus a partir de uma suspensão de célula
CA2776461C (en) 2009-10-15 2020-08-25 Crucell Holland B.V. Method for the purification of adenovirus particles.
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
PL2536829T3 (pl) 2010-02-15 2016-09-30 Sposób wytwarzania wektorów adenowirusowych Ad26
TWI539963B (zh) * 2010-07-09 2016-07-01 庫賽爾荷蘭公司 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
US20140248314A1 (en) * 2011-05-13 2014-09-04 Novartis Ag Pre-fusion rsv f antigens
CN104379733B (zh) 2012-03-12 2016-01-20 克鲁塞尔荷兰公司 具改变末端的重组腺病毒群
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
JP2013247240A (ja) 2012-05-25 2013-12-09 Gigaphoton Inc レーザ装置
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
KR102201554B1 (ko) 2013-04-15 2021-01-12 얀센 백신스 앤드 프리벤션 비.브이. Ｒｓｖ ｇ 단백질에 결합하는 인간 항체
US10035842B2 (en) 2013-04-15 2018-07-31 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
EP3488864A1 (en) 2013-04-25 2019-05-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3010931B1 (en) 2013-06-17 2018-06-13 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2015013551A1 (en) 2013-07-25 2015-01-29 Marshall Christopher Patrick Conformationally stabilized rsv pre-fusion f proteins
CN105530917B (zh) 2013-09-19 2020-06-05 扬森疫苗与预防公司 改进的腺病毒配制品
PE20190433A1 (es) * 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
MD3439672T2 (ro) * 2016-04-05 2021-04-30 Janssen Vaccines & Prevention Bv Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV

Also Published As

Publication number Publication date
EA039803B1 (ru) 2022-03-15
US20210101940A1 (en) 2021-04-08
JP2016520039A (ja) 2016-07-11
CN110590916A (zh) 2019-12-20
MX2015014890A (es) 2016-03-09
RS58436B1 (sr) 2019-04-30
EA035522B1 (ru) 2020-06-29
EP2988780B1 (en) 2018-12-26
ZA201507912B (en) 2022-03-30
EP3488864A1 (en) 2019-05-29
MY201791A (en) 2024-03-18
EP2988780A1 (en) 2016-03-02
CL2015003124A1 (es) 2016-05-13
EA202090675A3 (ru) 2020-08-31
TR201902513T4 (tr) 2019-03-21
JP6469081B2 (ja) 2019-02-13
MX361774B (es) 2018-12-17
AR096113A1 (es) 2015-12-09
WO2014174018A1 (en) 2014-10-30
CN105188745A (zh) 2015-12-23
CN105188745B (zh) 2019-10-18
KR102236497B1 (ko) 2021-04-06
CY1121600T1 (el) 2020-05-29
US10899800B2 (en) 2021-01-26
US20160102123A1 (en) 2016-04-14
PL2988780T3 (pl) 2019-06-28
US20230265127A1 (en) 2023-08-24
SI2988780T1 (sl) 2019-05-31
EA202090675A2 (ru) 2020-06-30
AU2014259474B2 (en) 2018-09-13
CA2910067A1 (en) 2014-10-30
SG11201508567XA (en) 2015-11-27
KR20160002938A (ko) 2016-01-08
LT2988780T (lt) 2019-03-12
ME03442B (me) 2020-01-20
AU2014259474A1 (en) 2015-11-05
DK2988780T3 (en) 2019-04-08
EA201592048A1 (ru) 2016-04-29
ES2715378T3 (es) 2019-06-04
TWI663175B (zh) 2019-06-21
PH12015502377A1 (en) 2016-02-22
IL242186B (en) 2020-07-30
HUE041659T2 (hu) 2019-05-28
HRP20190175T1 (hr) 2019-03-22
HK1220124A1 (en) 2017-04-28
AP2015008815A0 (en) 2015-10-31
PH12015502377B1 (en) 2021-09-08
NZ713371A (en) 2021-02-26
SMT201900138T1 (it) 2019-05-10
MY181066A (en) 2020-12-17
TW201520221A (zh) 2015-06-01
PT2988780T (pt) 2019-03-25
CA2910067C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
PH12015502735B1 (en) Stabilized soluble pre-fusion rsv f polypeptides
NZ733174A (en) Quinazoline derivatives used to treat hiv
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
CL2017002709A1 (es) Compuestos de pirazolo - y triazolo - pirimidina antivirales contra vsr
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
PH12015501156A1 (en) Pharmaceutical compositions
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
IN2013MU01749A (es)
CR20150648A (es) Derivados de nucleósido 4´-azido, 3´-desoxi-3´-fluoro sustituido
CO2018007669A2 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
EA201790495A1 (ru) Фармацевтические композиции длительного действия
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
CL2015003752A1 (es) Inhibidores de replicación viral, su proceso de preparación y sus uso terapeutico
BR112015022134A2 (pt) composto, composição farmacêutica, adesivo, bastão, dispensador de spray, tubo ou caneta, e, método de tratamento de uma infecção
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
MY169312A (en) An antiviral pharmaceutical composition